Biomarkers: predicting response to treatment
pNETs frequently contain mutations in MEN1, ATRX, DAXX, and the PI3K/AKT/mTOR pathway. However, more data are needed to determine whether this information can predict response to standard treatments, such as CAPTEM. At NANETS 2022, Hendifar et al. presented retrospective data on 25 patients with well-differentiated grade 1 and 2 pNETs who had received CAPTEM as first- or second-line treatment and whose tumors had been molecularly characterized through next-generation sequencing (NGS).